HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04336748|
Recruitment Status : Withdrawn (Not feasible)
First Posted : April 7, 2020
Last Update Posted : April 12, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Aim: To demonstrate the efficacy of low-dose hydroxychloroquine as primary prevention in healthcare workers Design, participants and interventions: Prospective, randomized, parallel group, double-blinded, placebo controlled, study.
including 440 participants who will be randomised to 2 treatment arms: hydroxychloroquine or placebo.
Outcome variables: symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR, viral load during SARS-CoV-2 infection, seroconversion during the study period, incidence of any acute respiratory infection, days of sick leave.
Statistical considerations: No trials have been published investigating the efficacy of HCQ as primary prophylaxis of SARS-CoV-2 infection in health care workers. Thus, sample size calculations in the proposed trial are based on the investigators' best estimates for several parameters.
In accordance to the effect of oseltamivir against symptomatic influenza, we assumed an approximate effectiveness of approximately 60% (HR of 0.4) (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464969/) as realistic. As a prophylactic intervention with HCQ, which may have side effects and for which supply shortage can be expected, was judged justifiable only if its effectiveness is high, we based our sample size consideration on a HR of 0.3. To estimate the probability of an event in both the experimental and the control group, very little data is available. In a Dutch point-prevalence study 0-10% of health-care workers were infected depending on the healthcare institution, depending on the hospital. This point-prevalence study was performed between 6 and 9 March, when the reported number of cases in the Netherlands was 33 and 77, respectively, according to the RIVM (https://www.rivm.nl/nieuws/resultaat-steekproef-4-ziekenhuismedewerkers-heeft-coronavirus). Additionally, in an a report published in the Lancet, 20% of responding healthcare workers in Italy were found to be infected with SARS-CoV2 within less than one month (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30627-9/fulltext). Several media reports indicate that this proportion is similar across various healthcare institutions and countries (https://www.nytimes.com/2020/03/24/world/europe/coronavirus-europe-covid-19.html) and (https://www.aljazeera.com/news/2020/03/spain-tightens-restrictions-week-lockdown-begins-200330191539568.html).
As the proposed study will be performed in a high-risk setting, we assumed an event (i.e. PCR positivity) probability of 10% in the control group and 3% in the experimental arm after the maximum study period. In summary, a sample size of 210 participants per arm is necessary to detect a HR of 0.3 with a power of 80.3% with an alpha-error of 0.05. To account for drop-outs and asymptomatic, undetected infection at inclusion or past infection with existing immunity, an additional 10 participants will randomized per treatment arm. The overall study population is therefore 440 participants.
Statistical analysis will be based on two populations: A Modified Intention to Treat population excluding those who withdrew consent after randomization and those with a positive serology at baseline. And a per protocol population including all randomized subjects who completed at least 3 out of 4 follow-up visits and took at least 80% of all doses of study medication.
|Condition or disease||Intervention/treatment||Phase|
|Sars-CoV2 Infection Viral Healthcare Worker Prophylaxis||Drug: Hydroxychloroquine Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Low-dose Hydroxychloroquine for Primary Prophylaxis Against SARS-CoV-2 in Health-care Workers - a Randomized, Double-blind, Controlled Trial|
|Estimated Study Start Date :||April 2020|
|Estimated Primary Completion Date :||July 2020|
|Estimated Study Completion Date :||August 2020|
Active Comparator: Hydroxychloroquine
200mg once daily
low dose (200mg) Hydroxychloroquine once daily for 4 weeks
Placebo Comparator: Placebo
- Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR [ Time Frame: 4 weeks ]
- Viral load during SARS-CoV-2 infection [ Time Frame: 4 weeks ]
- Seroconversion during the study period [ Time Frame: 4 weeks ]
- Incidence of any acute respiratory infection [ Time Frame: 4 weeks ]
- Days of sick leave [ Time Frame: 4 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Health-care worker with frequent contact with confirmed COVID-19 patients
- No active or past infection with SARS-CoV-2
- 18 years of age or older
- No allergy or contraindication to hydroxychloroquine
- written informed consent
- Age of less than 18 years
- Pregnancy or lactation
- unwillingness to use effective contraception during the participation in the trial
- Use of concomitant medication that prolongs the QT interval
- Allergy or contraindication to hydroxychloroquine
- Retinopathy or maculopathy
- Neuromuscular diseases (i.e Myasthenia gravis, Parkinson's disease)
- G6PD Deficiency
|Responsible Party:||Matthias Vossen, Priv. Doz. Dr., Medical University of Vienna|
|Other Study ID Numbers:||
HCQ prophylaxis for COVID19
|First Posted:||April 7, 2020 Key Record Dates|
|Last Update Posted:||April 12, 2022|
|Last Verified:||April 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Molecular Mechanisms of Pharmacological Action